While the dollar amount is small, the cluster involves the CEO and three other C-suite officers selling within a week — unusual for a pre-commercial biotech with a single pipeline asset. This may signal insider caution ahead of a binary catalyst (sebetralstat data or regulatory update). Monitor for any 8-K or press release in the next 2-4 weeks. The historical calibration shows bearish calls on KALV have underperformed (avg T+20 alpha -9.3%), so this signal should be taken as a modest caution flag, not a strong short thesis.
Price Chart
Executive Summary
Three C-suite insiders at KalVista (CEO, CMO, CDO) sold a combined $87K in open-market sales on May 18, 2026, at $26.76/share. This follows a separate cluster of CMO and CFO sales on May 21-22 totaling $112K, including derivative exercises. Total insider selling of ~$199K over 7 days is modest relative to the $1.4B market cap (0.014%), but the cluster involves the CEO and multiple senior executives, which is notable for a pre-commercial biotech awaiting a pivotal catalyst.
Key Financial Metrics
Key Facts
- CEO Benjamin Palleiko sold 1,100 shares for $30K on May 18
- CMO Paul Audhya sold 1,000 shares for $28K on May 18, plus 2,685 shares for $72K on May 22
- CDO Christopher Yea sold 1,100 shares for $30K on May 18
- CFO Brian Piekos sold 1,489 shares for $40K on May 22
- Total open-market sales in cluster: $87K (0.006% of market cap)
- Combined with prior 5-day cluster: ~$199K total insider sales (0.014% of market cap)
- CMO and CFO also exercised stock options (non-cash) on May 21
- KalVista is a pre-revenue biotech with a $1.4B market cap, awaiting sebetralstat (hereditary angioedema) catalyst
Financial Impact
Total insider sales of ~$199K, or 0.014% of $1.4B market cap — economically trivial in absolute terms
Risk Factors
- Insider sales may be 10b5-1 plan-driven or for tax/estate planning, not informational
- Dollar amount is tiny relative to market cap — could be routine portfolio rebalancing
- Historical bearish calls on KALV have underperformed (avg T+20 alpha -9.3%)
- Pre-commercial biotech stock prices are driven by pipeline catalysts, not insider trading patterns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KALV-1779838419890 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 15-12G | — | awaiting T+1 | — | — |
Jun 17, 2026 15w ago | EFFECT | $27.00 awaiting T+1 | awaiting T+1 | — | — |
Jun 11, 2026 16w ago | 8-K | $26.99 awaiting T+1 | awaiting T+1 | — | — |
Jun 11, 2026 16w ago | Institutional Cluster | $27.00 $27.00 | · 0.00% | ▼ −0.54% | — |
May 19, 2026 19w ago | Insider Cluster | $26.81 $26.77 | ▲ +0.15% | ▲ +0.34% | — |
May 19, 2026 19w ago | Insider Cluster | $26.81 $26.77 | ▼ −0.15% | ▼ −0.34% | — |
Apr 29, 2026 22w ago | 8-K | $26.67 $26.66 | ▼ −0.04% | ▼ −1.06% | — |
Apr 17, 2026 24w ago | Insider Cluster | $20.48 $20.87 | ▼ −1.90% | ▼ −2.10% | — |
Feb 23, 2026 31w ago | Insider Cluster | $15.56 $15.77 | ▼ −1.35% | ▼ −0.61% | — |
Feb 23, 2026 31w ago | Insider Cluster | $15.56 $15.77 | ▼ −1.35% | ▼ −0.61% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access